×
News Home

Analyst Rating: Will Pacific Biosciences of California Inc (PACB) Stock Beat the Market?

Wednesday, May 18, 2022 01:43 PM | InvestorsObserver Analysts
Analyst Rating: Will Pacific Biosciences of California Inc (PACB) Stock Beat the Market?

InvestorsObserver is giving Pacific Biosciences of California Inc (PACB) an Analyst Rating Rank of 30, meaning PACB is ranked higher by analysts than 30% of stocks. The average price target for PACB is $20.333 and analyst’s rate the stock as a Buy.

Overall Score - 4
Wall Street analysts are rating PACB a Buy today. Find out what this means to you and get the rest of the rankings on PACB!

Why are Analyst Ratings Important?

A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement. InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.

What's Happening With Pacific Biosciences of California Inc Stock Today?

Pacific Biosciences of California Inc (PACB) stock is trading at $5.20 as of 1:42 PM on Wednesday, May 18, a loss of -$0.53, or -9.34% from the previous closing price of $5.73. The stock has traded between $5.20 and $5.75 so far today. Volume today is less active than usual. So far 4,548,473 shares have traded compared to average volume of 7,539,462 shares. Click Here to get the full Stock Report for Pacific Biosciences of California Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App